Literature DB >> 21219560

Liver and combined lung and liver transplantation for cystic fibrosis: analysis of the UNOS database.

Ronen Arnon1, Rachel A Annunziato, Tamir Miloh, Maria Padilla, Hiroshi Sogawa, Linda Batemarco, Asha Willis, Frederick Suchy, Nanda Kerkar.   

Abstract

A proportion of patients with CF develop cirrhosis and portal hypertension. LT and combined LLT are rarely performed in patients with CF. To determine the outcome of LT and LLT in patients with CF. Patients with CF who had LT or LLT between 10/1987 and 5/2008 were identified from UNOS database. A total of 182 children (<18 yr) and 48 adults underwent isolated LT for CF. Seven more children and eight adults with CF underwent combined LLT. One- and five-yr patient and graft survival were not significantly different in patients who underwent LT in comparison with patients who underwent LLT (patient survival: LT; 83.9%, 75.7%, LLT; 80%, 80%; graft survival: LT; 76.1%, 67.0%, LLT; 80.0%, 80.0%, respectively). The two major causes of death after LT were pulmonary disease (15 patients, 22.7%) and hemorrhage (12 patients, 18.2%). Bilirubin was identified as a risk factor for death, and previous liver transplant and prolonged cold ischemic time were identified as risk factors for graft loss in LT patients. LT is a viable option for children and young adults with CF and end-stage liver disease. Outcome of LLT patients with CF was comparable to the outcome of patients with CF who underwent isolated LT.
© 2011 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21219560     DOI: 10.1111/j.1399-3046.2010.01460.x

Source DB:  PubMed          Journal:  Pediatr Transplant        ISSN: 1397-3142


  8 in total

Review 1.  Hepatic Manifestations of Cystic Fibrosis.

Authors:  Sasan Sakiani; David E Kleiner; Theo Heller; Christopher Koh
Journal:  Clin Liver Dis       Date:  2019-02-21       Impact factor: 6.126

2.  A Propensity-matched Survival Analysis: Do Simultaneous Liver-lung Transplant Recipients Need a Liver?

Authors:  Kyle Freischlag; Brian Ezekian; Paul M Schroder; Michael S Mulvihill; Morgan L Cox; Matthew G Hartwig; Stuart Knechtle
Journal:  Transplantation       Date:  2019-08       Impact factor: 4.939

Review 3.  Lung transplantation: indications and contraindications.

Authors:  David Weill
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

4.  Under Utilization of Pancreas Transplants in Cystic Fibrosis Recipients in the United Network Organ Sharing (UNOS) Data 1987-2014.

Authors:  D J Usatin; E R Perito; A M Posselt; P Rosenthal
Journal:  Am J Transplant       Date:  2016-02-15       Impact factor: 8.086

5.  Single-Center Long-Term Analysis of Combined Liver-Lung Transplant Outcomes.

Authors:  Kyle William Freischlag; Julia Messina; Brian Ezekian; Michael S Mulvihill; Andrew Barbas; Carl Berg; Debra Sudan; John Reynolds; Matthew Hartwig; Stuart Knechtle
Journal:  Transplant Direct       Date:  2018-04-26

Review 6.  Expanding Indications for Liver Transplant: Tumor and Patient Factors.

Authors:  Kevin Ka-Wan Chu; Kelly Hiu-Ching Wong; Kenneth Siu-Ho Chok
Journal:  Gut Liver       Date:  2021-01-15       Impact factor: 4.519

Review 7.  Cystic fibrosis associated liver disease in children.

Authors:  Joseph J Valamparampil; Girish L Gupte
Journal:  World J Hepatol       Date:  2021-11-27

8.  Combined Liver-Lung-Kidney Transplant in a Patient with Cystic Fibrosis.

Authors:  Lori Shah; Geoffrey Dube; Lorna Dove; Amy C McLaughlin; Jean Emond; Lloyd Rattner; Frank D'Ovidio; Emily DiMango
Journal:  Am J Case Rep       Date:  2021-06-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.